News from the ALS TDI

August 20, 2010

In continuing efforts to refine its preclinical drug development program, the ALS Therapy Development Institute (ALS TDI) of Cambridge, Mass., has added a new research mouse model to its operations, along with two new projects aimed at helping researchers test and develop therapies in the new mouse.

The Institute also has increased its emphasis on the study and use of biological indicators called “biomarkers,” and is working on practices designed to hasten ALS drug development industry-wide.

Click here for the entire article.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: